Her research is primarily dedicated to emerging and respiratory viruses. In 2014, she was involved in Geneva in a Phase I/II clinical trial evaluating the safety and immunogenicity of the rVSV-ZEBOV Ebola vaccine. She subsequently oversaw the field implementation of ring vaccination trials with the same vaccine, which is now licensed and represents a cornerstone of outbreak response.

As an infectious diseases physician, she also led, in collaboration with Médecins Sans Frontières (MSF), the first large Ebola survivor clinic, enabling the systematic collection and reporting of clinical data. As the lead clinician at the Centre for Emerging Viral Diseases, she has contributed to the clinical and virological characterisation of patients treated at HUG for a range of emerging infections, including Ebola virus disease, hantavirus infections, SARS-CoV-2, mpox, and West Nile virus, often involving the use of novel or investigational therapeutics.

Building on her experience in clinical trials and cohort studies, she is currently the sponsor and coordinating principal investigator of the INFLUENT trial (INpatient inFLUENZA Treatment), a multicenter, investigator-initiated, placebo-controlled study evaluating the efficacy of baloxavir in hospitalised influenza patients. In parallel, she leads a cohort study aimed at the comprehensive clinical and immune-virological characterization of (re-)emerging viral infections through detailed clinical data collection and biobanking.